Schoevers RA

Default mode network functional connectivity following treatment with conventional antidepressants and (es)ketamine in major depressive disorder: A systematic review.

Lima Constantino J, de Jager JE, Nuninga JO +3

Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial.

Massetti S, Smith-Apeldoorn SY, Veraart JKE +6

ArticlePsychedelics

Attitudes of Mental Healthcare Professionals Towards the Use of Psychedelics in the Treatment of Substance Use Disorders: A Systematic Review.

van Dalen F, Tap SC, Venema SD +3

Predicting changes in depressive symptomatology following oral esketamine treatment in treatment-resistant depression: A machine-learning approach.

Lima Constantino J, Freimann TS, van Dalfsen JH +5

Effects of ketamine on sleep and circadian rhythmicity in major depressive disorder and bipolar disorder: A systematic review.

Boesjes R, Oosterveld C, Kamphuis J +3

A call for the systematic assessment of sexual adverse events in ketamine and esketamine trials and clinical practice.

Smith-Apeldoorn SY, Veraart JKE, Kamphuis J +1

The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine.

Coerts DT, Smith-Apeldoorn SY, Oude Nijhuis JC +6

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Goodwin GM, Aaronson ST, Alvarez O +23

ATP-binding cassette transporter polymorphisms and the pharmacokinetics of oral esketamine.

Oude Nijhuis JC, Coerts DT, van Dalfsen JH +6

The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double-Blind Randomized Placebo-Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality.

Strous JFM, Roelandt GHJ, van Dalfsen JH +3

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

Goodwin GM, Aaronson ST, Alvarez O +28

Concomitant use of antidepressants and classic psychedelics: A scoping review.

Tap SC, Thomas K, Páleníček T +4

Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study.

Veraart JKE, Vos CF, Punt NC +6

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.

Veraart JK, Smith-Apeldoorn SY, van der Meij A +3

The Association between Intranasal Esketamine and Treatment-emergent Insomnia in the Treatment of Treatment-resistant Major Depression: A Meta-analysis.

Türkmen C, Boesjes R, Zandbergen AF +4

Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment.

Veraart JKE, Smith-Apeldoorn SY, Kamphuis J +2

Oral Esketamine as Alternative for Maintenance Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Case Series.

Coerts DT, Veraart JKE, Kamphuis J +3

Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers.

Constantino JL, van Dalfsen JH, Massetti S +2

Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review.

Lima Constantino J, Godschalk M, van Dalfsen JH +5

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Goodwin GM, Aaronson ST, Alvarez O +28

Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.

Seybert C, Schimmers N, Silva L +6

Psychedelics as a potential treatment for tobacco use disorder: a systematic review.

Spoelstra SK, Schoevers RA, Venema SD +1

Europe PMC2024

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.

Smith-Apeldoorn SY, Veraart JKE, Kamphuis J +5

Europe PMC2024

Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder.

Veraart JKE, van Westenbrugge M, van Wulfften Palthe JE +3

Europe PMC2023

Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder

Veraart JKE, van Westenbrugge M, van Wulfften Palthe JE +3

Europe PMC2023

ArticleMDMA

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.

Breeksema JJ, Kuin BW, Kamphuis J +3

Europe PMC2022

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.

Schimmers N, Breeksema JJ, Smith-Apeldoorn SY +3

Europe PMC2022

Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies.

Breeksema JJ, Niemeijer AR, Krediet E +2

Europe PMC2020

[Psychedelics for existential distress in terminally ill patients].

Schimmel N, Breeksema JJ, Veraart JKE +2

Europe PMC2020